EMA has most advanced policies on conflict of interest issues, says ECA report

11 October 2012

A review by the European Court of Auditors of the management of conflicts of interests in four independent agencies of the European Union found that the European Medicines Agency has some of the most advanced policies and procedures for declaring, assessing and managing potential conflicts of interests in place.

The report, which is based on policies and rules in place a year ago when the Court began its work, also makes a number of recommendations, many of which have already been implemented but noting that there is some scope for further improvements.

Guido Rasi, the EMA's executive director, said that the Agency "is committed to continuous review and improvement of its handling of conflicts of interests. We will look carefully at the recommendations of the Court, together with the European Commission, the other EU agencies and our national counterparts in the European medicines network."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology